A Pharmacodynamic Study of Rivaroxaban in Subjects Who Have Undergone Roux-en-Y Gastric Bypass Surgery

Trial Profile

A Pharmacodynamic Study of Rivaroxaban in Subjects Who Have Undergone Roux-en-Y Gastric Bypass Surgery

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Vascular disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Jan 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 05 Jan 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 05 Jan 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top